Carlsmed, Inc.
Income Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $50.5M | $27.2M |
| Cost of Revenue | $12.5M | $7.1M |
| Gross Profit | $38.0M | $20.0M |
| Gross Margin | 75.3% | 73.8% |
| Operating Expenses | ||
| Research & Development | $17.0M | $14.3M |
| SG&A Expense | $16.6M | $8.4M |
| Operating Income | $-30.6M | $-24.1M |
| Operating Margin | -60.5% | -88.8% |
| Interest Expense | $1.4M | $1.3M |
| Pretax Income | — | — |
| Income Tax Expense | $0 | $0 |
| Net Income | $-29.6M | $-24.3M |
| Net Margin | -58.7% | -89.3% |
| EPS (Basic) | $-2.12 | $-2.04 |
| EPS (Diluted) | $-2.12 | $-2.04 |
| Shares Outstanding (Basic) | 14.2M | 12.2M |
| Shares Outstanding (Diluted) | 14.2M | 12.2M |
| Dividends Per Share | — | — |